Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MREO
stocks logo

MREO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.000
-98.16%
--
--
-0.002
-89.59%
--
--
-0.004
-79.17%
Estimates Revision
The market is revising Downward the revenue expectations for Mereo BioPharma Group plc (MREO) for FY2025, with the revenue forecasts being adjusted by -29.81% over the past three months. During the same period, the stock price has changed by 15.25%.
Revenue Estimates for FY2025
Revise Downward
down Image
-29.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.2%
In Past 3 Month
Stock Price
Go Up
up Image
+15.25%
In Past 3 Month
Wall Street analysts forecast MREO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MREO is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MREO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MREO is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.040
sliders
Low
5.00
Averages
7.33
High
9.00
Current: 2.040
sliders
Low
5.00
Averages
7.33
High
9.00
JPMorgan
NULL -> Overweight
upgrade
$7 -> $8
2025-08-25
Reason
JPMorgan
Price Target
$7 -> $8
2025-08-25
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Mereo BioPharma to $8 from $7 and keeps an Overweight rating on the shares. The firm updated the company's model.
Needham
Gil Blum
Buy
downgrade
$7 -> $5
2025-07-10
Reason
Needham
Gil Blum
Price Target
$7 -> $5
2025-07-10
downgrade
Buy
Reason
Needham analyst Gil Blum lowered the firm's price target on Mereo BioPharma to $5 from $7 but keeps a Buy rating on the shares. The company announced that the Phase 3 Orbit study will continue towards a final analysis expected in Q4 after missing on its second interim, and this outcome represents the firm's downside scenario, though Needham's overall view on setrusumab's ultimate likelihood of success remains unchanged, given that about 80% alpha spend is reserved for the final analysis, the analyst tells investors in a research note.
Needham
Gil Blum
Strong Buy
Reiterates
$7
2025-04-09
Reason
Needham
Gil Blum
Price Target
$7
2025-04-09
Reiterates
Strong Buy
Reason
JP Morgan
Priyanka Grover
Buy
Initiates
$7
2025-03-27
Reason
JP Morgan
Priyanka Grover
Price Target
$7
2025-03-27
Initiates
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$7
2025-03-26
Reason
Needham
Gil Blum
Price Target
$7
2025-03-26
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$7
2025-03-18
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$7
2025-03-18
Reiterates
Buy
Reason
Group Dinner Meeting to be held in London, England on March 13 hosted by Cantor Fitzgerald.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mereo BioPharma Group PLC (MREO.O) is -97.48, compared to its 5-year average forward P/E of -83.00. For a more detailed relative valuation and DCF analysis to assess Mereo BioPharma Group PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-83.00
Current PE
-97.48
Overvalued PE
18.41
Undervalued PE
-184.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.03
Undervalued EV/EBITDA
-7.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.51
Current PS
0.00
Overvalued PS
18.93
Undervalued PS
0.09
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MREO News & Events

Events Timeline

(ET)
2025-11-24
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-21 (ET)
2025-11-21
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-10 (ET)
2025-11-10
16:05:34
Mereo BioPharma Announces Q3 Earnings Per Share of 1 Cent, Exceeding Consensus of 0 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
09-02Globenewswire
Investor Notice: Pomerantz Law Firm Probes Allegations for Mereo BioPharma Group plc Investors - MREO

  • Investigation into Mereo BioPharma: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Mereo BioPharma Group plc and its executives, urging affected investors to reach out for assistance.

  • Impact of Clinical Trial News: Following the announcement of the Phase 3 study progress for UX143, Mereo's stock price dropped significantly, closing at $1.69 per share after a 42.52% decline.

[object Object]
Preview
7.0
08-29Globenewswire
Investor Notice: Pomerantz Law Firm Probes Allegations for Mereo BioPharma Group plc Investors - MREO

Investigation Announcement

  • Investigation by Pomerantz LLP: Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Mereo BioPharma Group plc and its officers or directors. Investors are encouraged to reach out for more information.

Recent Developments

  • Orbit Study Update: On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced progress in the Phase 3 Orbit study for UX143 (setrusumab) aimed at treating osteogenesis imperfecta in pediatric and young adult patients. A final analysis is expected by the end of the year.

  • Stock Price Reaction: Following the announcement, Mereo's American Depositary Receipt (ADR) price dropped significantly, falling by $1.25 per share, which is a 42.52% decrease, closing at $1.69 per share on July 10, 2025.

Pomerantz Firm Background

  • Firm's Reputation: Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 80 years in fighting for victims of securities fraud and corporate misconduct. The firm has successfully recovered multimillion-dollar damages for class members in the past.

  • Contact Information: Investors seeking more information can contact Danielle Peyton at Pomerantz LLP via email or phone.

[object Object]
Preview
7.0
08-21Globenewswire
Investor Notice: Pomerantz Law Firm Probes Allegations for Mereo BioPharma Group plc Investors - MREO

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud or unlawful practices by Mereo BioPharma Group plc and its officers/directors, urging affected investors to contact them.

  • Recent Developments: On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced progress in a Phase 3 study for UX143 (setrusumab) with a final analysis expected by year-end.

  • Stock Price Impact: Following the announcement of the study's progress, Mereo's ADR price dropped significantly by 42.52%, closing at $1.69 per share on July 10, 2025.

  • Pomerantz Firm Background: The Pomerantz Firm, established over 80 years ago, specializes in corporate, securities, and antitrust class litigation, advocating for victims of securities fraud and corporate misconduct.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mereo BioPharma Group PLC (MREO) stock price today?

The current price of MREO is 2.04 USD — it has increased 4.08 % in the last trading day.

arrow icon

What is Mereo BioPharma Group PLC (MREO)'s business?

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.

arrow icon

What is the price predicton of MREO Stock?

Wall Street analysts forecast MREO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MREO is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mereo BioPharma Group PLC (MREO)'s revenue for the last quarter?

Mereo BioPharma Group PLC revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Mereo BioPharma Group PLC (MREO)'s earnings per share (EPS) for the last quarter?

Mereo BioPharma Group PLC. EPS for the last quarter amounts to -0.01 USD, decreased -50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mereo BioPharma Group PLC (MREO)'s fundamentals?

The market is revising Downward the revenue expectations for Mereo BioPharma Group plc (MREO) for FY2025, with the revenue forecasts being adjusted by -29.81% over the past three months. During the same period, the stock price has changed by 15.25%.
arrow icon

How many employees does Mereo BioPharma Group PLC (MREO). have?

Mereo BioPharma Group PLC (MREO) has 36 emplpoyees as of December 05 2025.

arrow icon

What is Mereo BioPharma Group PLC (MREO) market cap?

Today MREO has the market capitalization of 321.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free